{"id":"NCT03188185","sponsor":"Alkermes, Inc.","briefTitle":"A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)","officialTitle":"A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-12","primaryCompletion":"2020-02-26","completion":"2020-03-05","firstPosted":"2017-06-15","resultsPosted":"2021-03-15","lastUpdate":"2021-04-08"},"enrollment":278,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"ALKS 5461","otherNames":[]},{"type":"DRUG","name":"ALKS 5461 Placebo","otherNames":[]}],"arms":[{"label":"ALKS 5461","type":"EXPERIMENTAL"},{"label":"ALKS 5461 Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.","primaryOutcome":{"measure":"Change From Baseline to the End of Treatment (EOT) in the Montgomery Asberg Depression Rating Scale-10 (MADRS-10) Scores","timeFrame":"Baseline and 5 weeks for Stage 1, Baseline and 6 weeks for Stage 2","effectByArm":[{"arm":"S1: Placebo","deltaMin":-11.4,"sd":0.7},{"arm":"S1: ALKS 5461 2mg/2mg","deltaMin":-13.9,"sd":1.12},{"arm":"S2: Placebo","deltaMin":-4.2,"sd":1.06},{"arm":"S2: ALKS 5461 2mg/2mg","deltaMin":-4.7,"sd":1.11}],"pValues":[{"comp":"OG000 vs OG001 vs OG002 vs OG003","p":"0.128"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":35,"countries":["United States","Australia","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":198},"commonTop":["Nausea","Dizziness","Headache","Somnolence","Sedation"]}}